Singulair Indications/Uses

MONTELUKAST (SINGULAIR) is indicated in adult and pediatric patients 6 months of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction.
MONTELUKAST (SINGULAIR) is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. MONTELUKAST (SINGULAIR) and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability.
MONTELUKAST (SINGULAIR) is indicated for the relief of daytime and nighttime symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older), including nasal congestion, rhinorrhea, nasal itching, sneezing; nasal congestion upon awakening, difficulty going to sleep, and nighttime awakenings; tearing, itchy, red, and puffy eyes.